Advances in Acute Ischemic Stroke Management

Abstract

Acute ischemic stroke (AIS) remains a leading cause of morbidity and mortality worldwide, necessitating continual advancements in its management. This review synthesizes the latest evidence-based strategies, highlighting epidemiological trends, pathophysiological mechanisms, risk factors, clinical features, diagnostic modalities, and evolving therapeutic approaches. Emphasis is placed on recent advances such as mechanical thrombectomy, extended time windows for intervention, and emerging pharmacological therapies. Current guideline recommendations are discussed to provide clinicians with a comprehensive and practical summary of the evolving landscape in AIS care, with expert insights into future directions and ongoing challenges.

Introduction

Acute ischemic stroke is a time-critical neurological emergency resulting from cerebral arterial occlusion, leading to neuronal injury and potential long-term disability. The past decade has witnessed significant progress in the understanding and management of AIS, driven by robust clinical trials and technological innovation. Optimizing patient outcomes requires a nuanced understanding of the disease process, risk stratification, and rapid implementation of evidence-based interventions. This article reviews the latest advances in AIS management, providing clinicians with an authoritative resource for contemporary practice.

Epidemiology / Disease Burden

Stroke is a global health burden, representing the second leading cause of death and a primary source of adult disability. Ischemic strokes account for approximately 85% of all strokes, with an estimated 12 million new cases annually worldwide. The incidence is higher in older adults, but trends show an increasing prevalence among younger populations due to shifting risk factor profiles. Socioeconomic disparities contribute to variations in stroke incidence and outcomes, with low- and middle-income countries bearing a disproportionate share of the burden. The economic impact of AIS is substantial, encompassing direct healthcare costs and indirect losses from reduced productivity and long-term care needs.

Pathophysiology

AIS occurs when a thrombus or embolus occludes a cerebral artery, resulting in a cascade of ischemic injury. The core infarct region undergoes irreversible neuronal death within minutes, while the surrounding penumbra remains potentially salvageable for a limited period. Cellular energy failure, excitotoxicity, oxidative stress, inflammation, and disruption of the blood-brain barrier are key mechanisms driving tissue damage. The pathophysiological understanding of penumbral salvage has driven the development of reperfusion therapies, aiming to restore perfusion before irreversible injury ensues.

Risk Factors

Major modifiable risk factors for AIS include hypertension, atrial fibrillation, diabetes mellitus, dyslipidemia, and smoking. Non-modifiable risks encompass advanced age, male sex, and genetic predisposition. Emerging evidence implicates chronic kidney disease, obstructive sleep apnea, and inflammatory states as additional contributors. Identification and management of risk factors are central to both primary and secondary stroke prevention strategies.

Clinical Features

The clinical presentation of AIS is variable, dictated by the location and extent of cerebral ischemia. Classic symptoms include sudden onset of unilateral weakness, speech disturbances (aphasia or dysarthria), visual field deficits, and sensory loss. Less common manifestations involve altered consciousness or ataxia. Rapid recognition using validated stroke scales (e.g., NIHSS, FAST) is critical to expedite diagnostic and therapeutic processes.

Diagnosis

Prompt and accurate diagnosis of AIS is paramount. Non-contrast computed tomography (CT) remains the imaging modality of choice for early exclusion of hemorrhage. Advanced imaging techniques, such as CT angiography, CT perfusion, and magnetic resonance imaging (MRI) with diffusion-weighted imaging (DWI), provide detailed assessment of vascular occlusion and penumbral tissue. Biomarkers and point-of-care testing are under investigation to further enhance diagnostic speed and precision. Early electrocardiographic and laboratory evaluation aids in identifying stroke etiology and comorbidities.

Treatment & Management

Current management of AIS revolves around rapid reperfusion and supportive care. Intravenous thrombolysis with alteplase within 4.5 hours of symptom onset remains the standard of care for eligible patients. Strict adherence to blood pressure control, glycemic management, and prevention of complications (such as aspiration pneumonia and deep vein thrombosis) is essential. Multidisciplinary stroke units are associated with improved functional outcomes and reduced mortality. Secondary prevention strategies, including antiplatelet therapy, statins, and management of atrial fibrillation, are critical to reduce recurrent events.

Recent Advances / Emerging Therapies

Recent years have seen paradigm shifts in AIS management, particularly with the advent of mechanical thrombectomy for large vessel occlusions. Landmark trials (e.g., MR CLEAN, DAWN, DEFUSE 3) have expanded the therapeutic window for thrombectomy up to 24 hours in selected patients based on advanced imaging criteria. Novel thrombolytic agents, such as tenecteplase, are being evaluated for enhanced efficacy and safety profiles. Neuroprotective strategies and adjunctive therapies, including hypothermia, stem cell therapy, and targeted anti-inflammatory agents, represent promising avenues under investigation. The integration of artificial intelligence for imaging interpretation and workflow optimization is poised to further improve time-to-treatment and outcomes.

Guideline Recommendations

International guidelines, including those from the American Heart Association/American Stroke Association and European Stroke Organisation, emphasize early recognition, rapid imaging, and timely reperfusion therapy as cornerstones of AIS care. Mechanical thrombectomy is recommended for eligible patients with large vessel occlusions within 6 hours, and up to 24 hours in selected cases. Blood pressure management, antithrombotic therapy, and multidisciplinary care pathways are strongly endorsed. Recommendations are continually updated to incorporate new evidence regarding extended time windows, imaging selection, and emerging therapies, underscoring the importance of ongoing clinician education and system-level preparedness.

Conclusion

The management of acute ischemic stroke has undergone substantial evolution, with significant improvements in diagnostic precision, reperfusion strategies, and patient outcomes. The expanding therapeutic window for intervention, emerging pharmacological and device-based therapies, and guideline-driven multidisciplinary care are transforming the clinical landscape. Continued research, innovation, and equitable access to advanced stroke care remain imperative to further reduce the burden of AIS and enhance quality of life for survivors.